Overview
An acclaimed physician-scientist with a focus on urologic oncology, Dr. Loda uses biochemical and genomic approaches to investigate the mechanisms by which prostate cancer hijacks cell metabolism to allow tumors to flourish.
Highlights
- 1Nature communications · 2024
- 2Molecular cancer research : MCR · 2021
- 3Science signaling · 2024
Publications
Funding
Active
6 grants- Sub-PIKUL 253649-01PRORUST: Exploiting lipid metabolic vulnerabilities to trigger prostate tumor cell death (Collab Agreement w/ J. Swinnen). Originating sponsor is Fonds voor Wetenschappelijk Onderzoek aka FWO.Fonds voor Wetenschappelijk Onderzoek Vlaanderen · 2025–2030 · via Katholieke Universiteit Leuven
- Sub-PIHT9425-24-1-1116HEROIC Prostate Cancer Precision Health (PCaPH) Africa1K: Powering Precision Health to Improve Prostate Cancer Outcomes in AfricaU.S. Department of Defense · 2024–2028 · via University of Sydney
- PIHT9425-25-1-0385Genomically-informed Morphological Stromal Signatures to Predict Lethal Prostate CancerU.S. Department of Defense · 2025–2028
- MPIP01CA265768-05Investigating cell-intrinsic and extrinsic interactions in prostate cancer at the single cell level ("Core A: Pathobiology")National Cancer Institute · 2022–2027 · via Columbia University
- Sub-PIR01CA259200-05Genomic Diversity of Prostate Cancer Across the African DiasporaNational Cancer Institute · 2022–2027 · via Dana-Farber Cancer Institute
- MPIAICF 241000-01The role of lipidomic and genetic alterations in the predictive response to AR selective inhibitor (ARSI) and in racial disparities in patients with metastatic castration-resistant prostate cancer (mCRPC).American Italian Cancer Foundation · 2025–2026
Completed grants (21)
- Sub-PIGIMR 213956-03High-risk prostate cancer in southern Africa, unravelling the genome and exposome (TARGET Africa)U.S. Department of Defense · 2022–2025 · via University of Sydney
- Sub-PIW81XWH-22-1087-1Neuronal function and incurable prostate cancerU.S. Department of Defense · 2022–2025 · via Cold Spring Harbor Laboratory
- KPGIRF 227268-01Colorectal Cancer (CRC) Cellular Heterogeneity, Metastasis, and a Spatially-resolved Molecular Atlas for ColonGastro-Intestinal Research Foundation · 2022–2025
- KPHT9425-24-1-0310Characterizing 3'-UTR biology as a mechanism of therapy response in high risk prostate cancer.U.S. Department of Defense · 2024–2025
- MPIAICF 231002-01Untangle The Role of Tumor Microenvironment in Prostate Cancer Initiation, Progression, and Metastatization With Single-Cell Analysis TechnologiesAmerican Italian Cancer Foundation · 2024–2025
- Co-IHT94252410381Decoding Bone Metastasis in Prostate Cancer: A Multimodal Approach Integrating Genomics and Imaging DataU.S. Department of Defense · 2024–2024
- KPAICF 230990-01Loss of Stromal Androgen Receptor (AR) Signaling Contributes to Progression in Prostate CancerAmerican Italian Cancer Foundation · 2023–2024
- KPFAIRC 215049-01Deciphering the role of androgen receptor in spatially resolved mesenchymal populations in prostate cancerFondazione AIRC per la Ricerca sul Cancro · 2022–2024No publications yet
- PIPCF 227920-01Targeting lipid metabolism and diet in patients with locally advanced prostate cancerProstate Cancer Foundation · 2023–2023
- PIW81XWH-19-1-0566Lipid elongation via ELOVL5: a novel target for advanced prostate cancerU.S. Department of Defense · 2019–2023
- MPIP50CA211024-03Weill Cornell Medicine (WCM) SPORE in Prostate CancerNational Cancer Institute · 2017–2023
- Sub-PIU01CA167552-10Cancer Epidemiology Cohort in Male Health ProfessionalsNational Cancer Institute · 2019–2022 · via Harvard School of Public Health
- PIW81XWH-17-1-0483Pharmacologic Inhibition of Lipogenesis Suppresses AR and Its Splice Variants to Inhibit Progression of Castration-Resistant Prostate CancerU.S. Department of Defense · 2019–2021
- Sub-PIP20CA233255-03Precision Interception of Aggressive Prostate Cancer in African American MenNational Cancer Institute · 2019–2021 · via Dana-Farber Cancer Institute
- Sub-PIR01CA187918-05Targeting the p110beta isoform of P13 kinase in prostate cancerNational Cancer Institute · 2019–2020 · via Dana-Farber Cancer Institute
- PIR01CA131945-10Molecular Link Between Metabolic Syndrome and Prostate CancerNCI · 2007–2019 · via NIH RePORTER
- MPIP50CA090381-15Gleason-based mRNA and Metabolomic Profiling to Predict Prostate Cancer ProgressNCI · 2002–2019 · via NIH RePORTER
- MPIP41RR011823-15PALMITOYLATION SIGNATURE IN PROSTATE CANCER CELL LINESNCRR · 2010–2011 · via NIH RePORTER
Honors & distinctions
- Member · National Academy of Medicine · 2024
- Member · Association of American Physicians
Clinical research
Active
1 study- PIGenomically Informed Morphological Stromal Signatures to Predict Lethal Prostate CancerWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
News mentions
- Prostate Cancer Foundation Awards Grants to Weill Cornell Medicine InvestigatorsMarch 26, 2026
Six researchers from Weill Cornell Medicine have received Young Investigator Awards from the Prostate Cancer Foundation.
- Drs. Silvia Formenti, Massimo Loda Elected to National Academy of MedicineOctober 21, 2024
Dr. Silvia Formenti, chair of the Department of Radiation Oncology, and Dr. Massimo Loda, chair of the Department of Pathology and Laboratory Medicine, have been elected to the National Academy of Medicine.
- Stromal Cells May Help Predict Prostate Cancer MetastasisJanuary 12, 2024
Non-cancerous cells called stromal cells, which are found in and around prostate tumors, may be useful in assessing these tumors’ potential to spread, and may even be targets for future prostate cancer treatments, according to a study led by researchers at Weill Cornell Medicine.
- Awards and Honors – December 30, 2022December 30, 2022
Awards, honors, prizes and achievements for the month of December.
- Awards and Honors Across Weill Cornell Medicine: September 30, 2021September 30, 2021
Awards, honors, prizes and achievements for the month of September.
Show 4 more mentions
- Awards and Honors Across Weill Cornell Medicine – June 30, 2021June 30, 2021
Awards, honors, prizes and achievements for the month of June.
- COVID-19 Testing Program Built From Ground Up Amid Escalating PandemicMay 21, 2020
In March, as the COVID-19 pandemic gained a visible foothold in New York City, Weill Cornell Medicine and NewYork-Presbyterian faced a task unlike any they had encountered before: How would they quickly establish a reliable diagnostic testing program to identify patients and healthcare workers who had been exposed to SARS-CoV-2 amid a rapidly escalating public health crisis?
- Dr. Tan A. Ince Named Chief of Pathology at NewYork-Presbyterian Brooklyn Methodist HospitalJanuary 7, 2020
Dr. Tan A. Ince has been named chief of pathology at NewYork-Presbyterian Brooklyn Methodist Hospital, effective February 1. Dr. Ince was also recruited to Weill Cornell Medicine as a professor of pathology and laboratory medicine.
- High-Fat Diet Contributes to Prostate Cancer ProgressionNovember 11, 2019
A high-fat diet increases prostate cancer tumor progression in mice by mimicking the effects of a cancer-promoting gene and may contribute to more aggressive cancer in humans, according to a study from Weill Cornell Medicine and Dana-Farber Cancer Institute investigators.
Media highlights
- These Drug Candidates Excited Researchers 10 Years Ago. What Happened?Chemical & Engineering News (C&EN) · September 1, 2026
External relationships
Professional Services
San Raffaele Scientific Institute